πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 68 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12121523

Method of treatment of attention deficit/hyperactivity disorder (ADHD)

Supernus Pharmaceuticals, Inc. Β· Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11911368

Method of treatment of CNS disorders

Supernus Pharmaceuticals, Inc. Β· Granted Tue Feb 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11896599

Modified release preparations containing oxcarbazepine and derivatives thereof

Supernus Pharmaceuticals, Inc. Β· Granted Tue Feb 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11638708

Method of treatment of aggression

Supernus Pharmaceuticals, Inc. Β· Granted Tue May 02 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11458143

Method of treatment of attention deficit/hyperactivity disorder (ADHD)

Supernus Pharmaceuticals, Inc. Β· Granted Tue Oct 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11351120

Use of higher doses of modified release huperzine formulations

Supernus Pharmaceuticals, Inc. Β· Granted Tue Jun 07 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11324753

Method of treatment of attention deficit/hyperactivity disorder (ADHD)

Supernus Pharmaceuticals, Inc. Β· Granted Tue May 10 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 05 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11166960

Modified release preparations containing oxcarbazepine and derivatives thereof

Supernus Pharmaceuticals, Inc. Β· Granted Tue Nov 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11077114

Stabilized formulations of CNS compounds

Supernus Pharmaceuticals, Inc. Β· Granted Tue Aug 03 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10314790

Sustained-release formulations of topiramate

Supernus Pharmaceuticals, Inc. Β· Granted Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 06 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10265319

Formulations of viloxazine

Supernus Pharmaceuticals, Inc. Β· Granted Tue Apr 23 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10220042

Modified release preparations containing oxcarbazepine and derivatives thereof

Supernus Pharmaceuticals, Inc. Β· Granted Tue Mar 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10201547

Method of treatment of aggression

Supernus Pharmaceuticals, Inc. Β· Granted Tue Feb 12 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 07 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10160733

Methods for producing viloxazine salts and novel polymorphs thereof

Supernus Pharmaceuticals, Inc. Β· Granted Tue Dec 25 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 20 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10149853

Stabilized formulations of CNS compounds

Supernus Pharmaceuticals, Inc. Β· Granted Tue Dec 11 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10058556

Method of treatment of aggression

Supernus Pharmaceuticals, Inc. Β· Granted Tue Aug 28 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 23 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10005743

Methods for producing viloxazine salts and novel polymorphs thereof

Supernus Pharmaceuticals, Inc. Β· Granted Tue Jun 26 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 21 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9855278

Modified release preparations containing oxcarbazepine and derivatives thereof

Supernus Pharmaceuticals, Inc. Β· Granted Tue Jan 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 28 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9801887

Method of treatment of aggression

Supernus Pharmaceuticals, Inc. Β· Granted Tue Oct 31 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9744137

Topiramate compositions and methods of enhancing its bioavailability

Supernus Pharmaceuticals, Inc. Β· Granted Tue Aug 29 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 24 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9662338

Formulations of viloxazine

Supernus Pharmaceuticals, Inc. Β· Granted Tue May 30 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 25 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9622983

Sustained-release formulations of topiramate

Supernus Pharmaceuticals, Inc. Β· Granted Tue Apr 18 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 13 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9603853

Formulations of viloxazine

Supernus Pharmaceuticals, Inc. Β· Granted Tue Mar 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9555004

Sustained-release formulations of topiramate

Supernus Pharmaceuticals, Inc. Β· Granted Tue Jan 31 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted